当前位置: 首页 >> 检索结果
共有 360 条符合本次的查询结果, 用时 5.1937335 秒

161. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.

作者: Sizheng Steven Zhao.;Selina Robertson.;Tzvi Reich.;Nicolas L Harrison.;Robert J Moots.;Nicola J Goodson.
来源: Rheumatology (Oxford). 2020年59卷Suppl4期iv47-iv57页
Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on axSpA outcomes.

162. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.

作者: Yantao Xu.;Yuting Li.;Mengyuan Dong.;Zi'ang Gao.;Xiang Chen.;Hong Liu.;Minxue Shen.
来源: Rheumatology (Oxford). 2020年59卷12期3657-3665页
We sought to systematically investigate the effectiveness of secukinumab in psoriatic arthritis (PsA) patients who previously received TNFs inhibitor (TNFi) treatment and those who were TNFi naïve.

163. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment.

作者: Piercarlo Sarzi-Puttini.;Valeria Giorgi.;Daniela Marotto.;Fabiola Atzeni.
来源: Nat Rev Rheumatol. 2020年16卷11期645-660页
Fibromyalgia is characterized by chronic widespread pain, fatigue, sleep disturbances and functional symptoms. The etiopathogenesis, diagnostic criteria and classification criteria of fibromyalgia are still debated and, consequently, so are the strategies for treating this condition. Fibromyalgia is the third most frequent musculoskeletal condition, and its prevalence increases with age. However, although diagnosis has improved with the evolution of more accurate diagnostic criteria, a considerable proportion of physicians still fail to recognize the syndrome. Many factors contribute to the development of fibromyalgia in a unique manner: genetic predisposition, personal experiences, emotional-cognitive factors, the mind-body relationship and a biopsychological ability to cope with stress. The multiple components of the pathogenesis and maintenance of the condition necessitate a multi-modal treatment approach. Individually tailored treatment is an important consideration, with the increasing recognition that different fibromyalgia subgroups exist with different clinical characteristics. Consequently, although an evidence-based approach to fibromyalgia management is always desirable, the approach of physicians is inevitably empirical, and must have the aim of creating a strong alliance with the patient and formulating shared, realistic treatment goals.

164. Sex steroids and autoimmune rheumatic diseases: state of the art.

作者: Maurizio Cutolo.;Rainer H Straub.
来源: Nat Rev Rheumatol. 2020年16卷11期628-644页
In autoimmune rheumatic diseases, oestrogens can stimulate certain immune responses (including effects on B cells and innate immunity), but can also have dose-related anti-inflammatory effects on T cells, macrophages and other immune cells. By contrast, androgens and progesterone have predominantly immunosuppressive and anti-inflammatory effects. Hormone replacement therapies and oral contraception (and also pregnancy) enhance or decrease the severity of autoimmune rheumatic diseases at a genetic or epigenetic level. Serum androgen concentrations are often low in men and in women with autoimmune rheumatic diseases, suggesting that androgen-like compounds might be a promising therapeutic approach. However, androgen-to-oestrogen conversion (known as intracrinology) is enhanced in inflamed tissues, such as those present in patients with autoimmune rheumatic diseases. In addition, it is becoming evident that the gut microbiota differs between the sexes (known as the microgenderome) and leads to sex-dependent genetic and epigenetic changes in gastrointestinal inflammation, systemic immunity and, potentially, susceptibility to autoimmune or inflammatory rheumatic diseases. Future clinical research needs to focus on the therapeutic use of androgens and progestins or their downstream signalling cascades and on new oestrogenic compounds such as tissue-selective oestrogen complex to modulate altered immune responses.

165. Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus.

作者: Francesca Ingegnoli.;Ariane L Herrick.;Tommaso Schioppo.;Francesca Bartoli.;Nicola Ughi.;John D Pauling.;Alberto Sulli.;Maurizio Cutolo.;Vanessa Smith.; .
来源: Rheumatology (Oxford). 2021年60卷3期1410-1418页
The level of detail included when describing nailfold videocapillaroscopy (NVC) methods varies among research studies, making interpretation and comparison of results challenging. The overarching objective of the present study was to seek consensus on the reporting standards in NVC methodology for clinical research in rheumatic diseases and to propose a pragmatic reporting checklist.

166. Access to paediatric rheumatology care in juvenile idiopathic arthritis: what do we know? A systematic review.

作者: Aurélie Chausset.;Bruno Pereira.;Stéphane Echaubard.;Etienne Merlin.;Caroline Freychet.
来源: Rheumatology (Oxford). 2020年59卷12期3633-3644页
This review examines time to access appropriate care for JIA patients and analyses the referral pathway before the first paediatric rheumatology (PR) visit. We also describe factors associated with a longer referral.

167. The relationship between periodontal status and rheumatoid arthritis - systematic review.

作者: Joanna Samborska-Mazur.;Dorota Sikorska.;Marzena Wyganowska-Świątkowska.
来源: Reumatologia. 2020年58卷4期236-242页
There have been numerous publications investigating the relationship between periodontitis (PD) and rheumatoid arthritis (RA) so far. This publication presents the common risk factors for the development of PD and RA. The major impact of the pathological bacterial factor and cigarette smoking with chronic inflammation playing the key role in both diseases has been confirmed by numerous studies in various populations over the years. More research focuses nowadays also on the role of improper diet and obesity. Pathophysiological pathways, such as increased concentration of proinflammatory cytokines, indirectly affecting the cardiovascular complications and coagulation disorders, which has an impact on function disorders of tissue metalloproteinase inhibitors and the plasminogen activation system, were also researched. This systematic review of current literature has shown numerous discrepancies in previous analyses and the need for further detailed research on the relationship between periodontal status and RA.

168. How long does a shoulder replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 10 years of follow-up.

作者: Jonathan P Evans.;Jonathan T Evans.;Richard S Craig.;Hasan R Mohammad.;Adrian Sayers.;Ashley W Blom.;Michael R Whitehouse.;Jonathan L Rees.
来源: Lancet Rheumatol. 2020年2卷9期e539-e548页
Shoulder replacement is an increasingly common treatment for end-stage degenerative shoulder conditions. Some shoulder replacements are unsuccessful and additional operations might be required. It is important for patients and clinicians to know how long shoulder replacements last and how effectively they reduce pain and improve function. This study aims to determine the longevity and long-term efficacy of shoulder replacements.

169. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties.

作者: Elisabetta Chessa.;Matteo Piga.;Alberto Floris.;Hervé Devilliers.;Alberto Cauli.;Laurent Arnaud.
来源: Rheumatology (Oxford). 2020年59卷12期3622-3632页
The Physician Global Assessment (PGA) is a visual analogue score that reflects the clinician's judgement of overall SLE disease activity. The aim of this systematic literature review is to describe and analyse the psychometric properties of the PGA.

170. A systematic review exploring the evidence reported to underpin exercise dose in clinical trials of rheumatoid arthritis.

作者: Graham Boniface.;Varsha Gandhi.;Meriel Norris.;Esther Williamson.;Shona Kirtley.;Neil E O'Connell.
来源: Rheumatology (Oxford). 2020年59卷11期3147-3157页
We aimed to evaluate the evidence reported to underpin exercise dose in randomised controlled trials (RCTs) using strengthening exercise in RA. We searched six different databases between 1 January 2000 and 3 April 2019. We included RCTs, where a main component of the intervention and/or control used strengthening exercise. Evidence sources cited to underpin dose were judged for their quality, consistency and applicability. Thirty-two RCTs were reviewed. Four (12.5%) piloted the intervention without using dose-escalation designs to determine optimal dose-response. Twenty (62.5%) reported no evidence underpinning dose. Where reported, quality, consistency and applicability of the underpinning evidence was a cause for methodological concern. The majority of RCTs did not report the evidence underpinning dose. When reported, the evidence was often not applicable to the clinical population. Frequently, the dose used differed to the dose reported/recommended by the underpinning evidence. Our findings illustrate exercise dose may not be optimised for use with clinical populations prior to evaluation by RCT.

171. The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence.

作者: Gerlienke E Geurts-Voerman.;Lise M Verhoef.;Bart J F van den Bemt.;Alfons A den Broeder.
来源: BMC Rheumatol. 2020年4卷37页
Dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs) is performed to achieve steady state drug concentrations earlier after treatment start compared to dosing regimens without loading. Although loading inherently results in increased costs, treatment targets in terms of reduced disease activity may be achieved at an earlier state. It is an interesting topic that, surprisingly, has not received much attention in literature.

172. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.

作者: Ana Rita Cruz-Machado.;Santiago Rodrigues-Manica.;Joana Leite Silva.;Irina Alho.;Constança Coelho.;Joana Duarte.;Cláudia Florêncio.;Fernando M Pimentel-Santos.;José Tavares-Costa.;Elsa Vieira-Sousa.
来源: Rheumatology (Oxford). 2020年59卷11期3158-3171页
To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA).

173. Temporal arteritis, Sjögren's syndrome and mixed pain components as manifestations in a diabetic older adult: systematic review based on a case report.

作者: Fernando M Runzer-Colmenares.;Ian Falvy-Bockos.;Diego Chambergo-Michilot.
来源: Reumatologia. 2020年58卷3期179-183页
Temporal arteritis (TA) is an inflammatory vascular disease common in the European population. It is mainly characterized by sudden onset headache. TA is rarely associated with other autoimmune diseases, such as Sjögren's syndrome (SS). We present the case of a Peruvian 71 year-old man with SS history, who was admitted to the emergency department due to severe headache evolved in 4 days, periocular pain and right ptosis. The authors also performed a systematic review of case reports or case series of patients diagnosed with both TA and SS. This temporal arteritis case is an atypical presentation because headache was characterized by mixed nociceptive and neuropathic pain components. Despite the infrequency, new studies should be carried out to identify comorbidities in TA patients.

174. Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study.

作者: Amber Vanhaecke.;Sofie De Schepper.;Sabrina Paolino.;Lise Heeman.;Hanne Callens.;Jan Gutermuth.;Sara Nguyen.;Maurizio Cutolo.;Vanessa Smith.
来源: Rheumatology (Oxford). 2020年59卷10期2725-2733页
SSc and localized sclerosis (LoS) are considered clinically distinct entities. We describe herein the coexistence of SSc and LoS by both a systematic literature review and an observational cohort study of unselected SSc patients.

175. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis.

作者: Jiawen Deng.;Zachary Silver.;Emma Huang.;Elena Zheng.;Kyra Kavanagh.;Aaron Wen.;Wei Cheng.;Johanna Dobransky.;Stephanie Sanger.;George Grammatopoulos.
来源: Rheumatology (Oxford). 2021年60卷2期649-657页
To perform a network meta-analysis (NMA) on the efficacy of antiosteoporotic interventions in the prevention of vertebral and non-vertebral fractures in adult patients taking glucocorticoids (GCs).

176. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.

作者: Jasmin B Kuemmerle-Deschner.;Raju Gautam.;Aneesh T George.;Syed Raza.;Kathleen G Lomax.;Peter Hur.
来源: Rheumatology (Oxford). 2020年59卷10期2711-2724页
To identify and summarize the existing evidence on the efficacy, effectiveness and safety of biologic therapies used, either as indicated or off-label, in the treatment of FMF.

177. The impact of smoking on prevalence of psoriasis and psoriatic arthritis.

作者: Ummugulsum Gazel.;Gizem Ayan.;Dilek Solmaz.;Servet Akar.;Sibel Z Aydin.
来源: Rheumatology (Oxford). 2020年59卷10期2695-2710页
In this systematic literature review and meta-analysis, we aimed to investigate the impact of cigarette smoking on the prevalence and incidence of psoriasis and psoriatic arthritis (PsA).

178. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.

作者: Natalia Cabrera.;Gabriela Avila-Pedretti.;Alexandre Belot.;Jean-Paul Larbre.;Sabine Mainbourg.;Agnès Duquesne.;Perrine Janiaud.;Behrouz Kassai.;Michel Cucherat.;Jean-Christophe Lega.
来源: Rheumatology (Oxford). 2020年59卷9期2226-2236页
To assess the net benefit of biological agents (BA) used in JIA.

179. Patients' attitudes and experiences of transition from paediatric to adult healthcare in rheumatology: a qualitative systematic review.

作者: Ayano Kelly.;Fiona Niddrie.;David J Tunnicliffe.;Andrea Matus Gonzalez.;Camilla Hanson.;Ivy Jiang.;Gabor Major.;Davinder Singh-Grewal.;Kathleen Tymms.;Allison Tong.
来源: Rheumatology (Oxford). 2020年59卷12期3737-3750页
We aimed to describe patients' attitudes and experiences of transition from paediatric to adult healthcare in rheumatology to inform patient-centred transitional care programmes.

180. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.

作者: Jun K Khoo.;Hayley Barnes.;Seraphina Key.;Ian N Glaspole.;Andrew J Östör.
来源: Rheumatology (Oxford). 2020年59卷9期2217-2225页
Small molecule tyrosine kinase inhibitors [smTKI, comprising mostly of Janus kinase (JAK) and to a lesser extent, spleen tyrosine kinase (SyK) inhibitors] modulate the cytokine receptor-mediated intracellular signal cascade, and are an effective treatment for autoimmune diseases and malignancies. As smTKI are novel, long-term safety is uncertain. Due to increasing use, characterization of their true adverse event profile is critical.
共有 360 条符合本次的查询结果, 用时 5.1937335 秒